Mayo Clinic ProceedingsChronic Necrotizing Pulmonary Aspergillosis: Pathologic Outcome After Itraconazole Therapy
Section snippets
MATERIAL AND METHODS
Three cases of cavitary CNPA were identified. Antemortem diagnosis was based on the criteria of Binder and coworkers2 and Gefter and associates.1 All patients had a compatible clinical history, subacute to chronic disease course, and pulmonary cavitation with or without infiltrates on a chest roentgenogram. Aspergillus was the sole pathogen isolated from sputum and bronchial washings or transthoracic needle aspirate. CNPA was confirmed histologically in all cases—by lobectomy in one and autopsy
RESULTS
Three cases of CNPA were identified; two were caused by A. fumigatus, and one was caused by A. flavus. All cases were diagnosed and treated by one of us. Itraconazole was administered as 200 mg orally twice a day for a duration that varied from 5 months to 1 year. All patients took itraconazole with meals and refrained from using H2 blockers and over-the-counter antacids during treatment. Details about the clinical and pathologic response to itraconazole are summarized in the subsequent
REPORT OF CASES
Case 1.—A 71-year-old male smoker with long-standing chronic obstructive pulmonary disease (COPD) sought medical assistance in 1991 because of a 2-month history of a cough productive of blood-tinged phlegm. His past medical history was pertinent for a lobectomy (left upper lobe) in 1982 for a stage I squamous cell carcinoma of the lung. After the operation, the patient continued to smoke and had periodic follow-up examinations and chest x-ray studies ordered by his referring physician.
In 1988,
DISCUSSION
In the 1980s, CNPA was described as a distinct type of pulmonary aspergillosis by both Gefter and associates1 and Binder and colleagues.2 Gefter and associates1 used the term semi-invasive aspergillosis to emphasize a disease process overlapping the extremes of colonization and frankly invasive disease. In reviewing the literature, Binder and colleagues2 cited case reports consistent with CNPA as far back as 1921. The terminology used to describe these cases included “primary pulmonary
CONCLUSION
Ultimately, the role of itraconazole in CNPA will require further study with larger numbers of patients, different drug doses and treatment durations, and more clearly defined endpoints. In addition, autopsy studies should be performed in all evaluable patients to obtain objective confirmation of the disease process and the results of therapy. Currently, no individual therapy for CNPA can be recommended as clearly superior to another. Because itraconazole improved patients symptomatically but
REFERENCES (32)
Case of aspergillosis treated with amphotericin “B”
Dis Chest
(1960)- et al.
Intracavitary amphotericin B in the treatment of symptomatic pulmonary aspergillomas
Am J Med
(1980) Serial studies in a case of pulmonary aspergillosis
Dis Chest
(1967)- et al.
Pulmonary aspergillosis: a case report
J Thorac Surg
(1958) - et al.
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents
Diagn Microbiol Infect Dis
(1992) Itraconazole therapy in aspergillosis: study in 49 patients
J Am Acad Dermatol
(1990)- et al.
Aspergillus pneumonia in association with an aspergilloma
Br J Dis Chest
(1968) - et al.
Invasive primary aspergillosis of the lung with cerebral metastasis and complete recovery
Dis Chest
(1962) - et al.
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis
Am J Med
(1994) - et al.
European experience with itraconazole in systemic mycoses
J Am Acad Dermatol
(1990)
“Semi-invasive” pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung
Radiology
Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity
Medicine
Gastrointestinal and liver diseases
Immunodeficiency states
5-Fluorocytosine treatment of meningeal and pulmonary aspergillosis
Am J Med
Pulmonary aspergillosis: a review and a description of three new cases
Thorax
Cited by (0)
The views expressed herein are those of the authors and do not purport to reflect the views of the US Army or the Department of Defense.